AFP, is a tumor-associated antigen with high expression in malignant hepatocytes but minimal presence in healthy adult tissues. Tacatuzumab binds to cell-surface-associated AFP, enabling targeted delivery of toxins (e.g., calicheamicin) or radioactive isotopes to cancer cells. This approach aims to minimize off-target effects while inducing apoptosis in AFP-positive tumors, offering a potential therapy for HCC with limited treatment options.